A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-06

Study Completion Date

2025-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal disease caused by Clostridium tetani infection. Currently, there is no clinical trial registration of Diphtheria, tetanus, and pertussis (DPT) vaccine applicable to ≥6 years of age in China, therefore, the five-component acellular DPT combination vaccine developed by our research has a promising future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .

NCT04099303

Diphtheria Tetanus Pertussis

COMPLETED PHASE1

A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

NCT06708286

Diphtheria Tetanus Pertussis

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

NCT06857370

Diphtheria, Tetanus and Acellular Pertussis

ACTIVE_NOT_RECRUITING PHASE3

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

NCT05951725

Diphtheria, Tetanus and Acellular Pertussis

ACTIVE_NOT_RECRUITING PHASE3

Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial

NCT07112144

Prevent Whooping Cough Prevent Diphtheria Prevent Tetanus

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The vaccines used in China's immunization program for the prevention of pertussis, tetanus and diphtheria include the adsorbed cell-free diphtheria-tetanus-acellular pertussis vaccine (DTaP) and the diphtheria-tetanus-acellular tetanus vaccine (DT) and tetanus vaccine. Among them, DTaP vaccination is for children from 3 months of age to 6 years of age, with one dose each at 3, 4, 5, and 18 months of age; DT vaccination is for children under 12 years of age, with one dose at 6 weeks of age after completing four doses of DTaP vaccination. However, infant and young child vaccination is no longer sufficient to prevent the threat of this disease, mainly due to the rapid decay of immune protection in adolescents and adults, and infections in this population, which are the main source of infection leading to infection in infants and young children, have been a number of new preventive strategies are being evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diphtheria Tetanus Pertussis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental vaccine group 1A,≥18 years old

1 dose of Tdcp vaccine

Group Type EXPERIMENTAL

Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)

Intervention Type BIOLOGICAL

1 dose of Tdcp vaccine (0.5ml) on Day 0

Control vaccine group 1B,≥18 years old

1 dose of PPV23 vaccine

Group Type ACTIVE_COMPARATOR

23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）

Intervention Type BIOLOGICAL

1 dose of PPV23 vaccine (0.5ml) on Day 0

Experimental vaccine group 2A,12~17 years old

1 dose of Tdcp vaccine

Group Type EXPERIMENTAL

Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)

Intervention Type BIOLOGICAL

1 dose of Tdcp vaccine (0.5ml) on Day 0

Control vaccine group 2B,12~17 years old

1 dose of PPV23 vaccine

Group Type ACTIVE_COMPARATOR

23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）

Intervention Type BIOLOGICAL

1 dose of PPV23 vaccine (0.5ml) on Day 0

Experimental vaccine group 3A,6~11 years old

1 dose of Tdcp vaccine

Group Type EXPERIMENTAL

Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)

Intervention Type BIOLOGICAL

1 dose of Tdcp vaccine (0.5ml) on Day 0

Control vaccine group 3B,6~11 years old

1 dose of DT vaccine

Group Type ACTIVE_COMPARATOR

Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)

Intervention Type BIOLOGICAL

1 dose of DT vaccine (0.5ml) on Day 0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)

1 dose of Tdcp vaccine (0.5ml) on Day 0

Intervention Type BIOLOGICAL

23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）

1 dose of PPV23 vaccine (0.5ml) on Day 0

Intervention Type BIOLOGICAL

Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)

1 dose of DT vaccine (0.5ml) on Day 0

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 6 years of age.
* Willingness to provide proof of identity.
* The informed consent of the volunteer and/or the guardian and/or the delegate must be obtained and the informed consent form must be signed.
* Volunteers are able and willing to comply with the requirements of the clinical trial protocol and are able to complete the full study follow up.
* Volunteers aged 6-11 years who have completed 4 doses of DPT-containing vaccine, but have not received the 5th dose, and have ≥3 years between the 4th dose.
* Volunteers aged ≥12 years must not have received any of the components of the DPT-containing vaccine within 5 years.

Exclusion Criteria

* Persons with fever prior to vaccination, with axillary temperature \> 37.0°C.
* A female with a positive urine pregnancy test or a breastfeeding volunteer, where the volunteer or her partner has a plan to become pregnant within 180 days.
* Adults with severe cardiovascular disease, hypertension (systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg) that cannot be controlled by medication, or other severe chronic diseases.
* Abnormal and clinically significant results of preimmunization blood tests, blood biochemistry and urine tests.
* Persons who have suffered from one of the diseases of diphtheria or tetanus, or who have suffered from whooping cough in the last three years.
* Volunteers ≥12 years of age who have received pneumococcal polysaccharide/conjugate-containing vaccine within 4 years.
* Individuals who have had household contact with individuals diagnosed with pertussis, diphtheria, tetanus in the past 30 days.
* Individuals who are allergic to the components of the study vaccine or who have developed an allergy during previous administration of the same vaccine; individuals with a previous history of severe allergies, such as urticaria, anaphylaxis, respiratory distress, angioneurotic edema, or asthma.
* History of convulsions, epilepsy, encephalopathy and serious neurological disorders (e.g., transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.), etc.
* Individuals with primary and secondary immune impairment (history of thyroid, pancreas, liver, spleen, kidney disease or removal, or need for treatment due to thyroid disease within the past 12 months), who have received immunosuppressive therapy within 3 months.
* Physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders.
* Persons with acute febrile illnesses and current patients with infectious diseases who have had a history of moderately high fever (axillary temperature ≥38.0°C) or cardiopulmonary disease (frequent asthma attacks) within the past 3 days.
* Has received another investigational drug or vaccine within 1 month prior to receiving the experimental drug, or is planning to participate or is participating in a clinical study of any other drug.
* Received live attenuated vaccine within 14 days prior to receiving the test drug and subunit vaccine or inactivated vaccine within 7 days prior to receiving the test drug.
* Any other factors that, in the judgment of the investigator, make the volunteer unsuitable for participation in a clinical trial.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes